Irritable Bowel Syndrome
International diagnostic criteria, Rome IV, released May 2016
Recurrent abdominal pain at least 1 day/week in the last
3 months associated with two or more of the following:
1. Related to defecation
2. change in frequency of stool
3. change in form (appearance) of stool
* Criteria fulfilled for the last 3 months with symptom onset
at least 6 months prior to diagnosis
Our mission is to improve the lives of people with Disorders of Gut-Brain Interaction. The Rome Foundation is an independent not for profit 501(c) 3 organization that provides support for activities designed to create scientific data and educational information to assist in the diagnosis and treatment of Disorders of Gut-Brain Interaction (DGBIs), formerly called Functional Gastrointestinal Disorders (FGIDs)
For almost three decades, the Rome organization has sought to legitimize and update our knowledge of the DGBIs. This has been accomplished by bringing together scientists and clinicians from around the world to classify and critically appraise the science of gastrointestinal function and dysfunction. This knowledge permits clinical scientists to make recommendations for diagnosis and treatment that can be applied in research and clinical practice.
The Rome Foundation is committed to the continuous development, legitimization and preservation of the field of DGBIs through science-based activities. We are inclusive and collaborative, patient-centered, innovative and open to new ideas. (From the Rome Foundation website. Quoted with permission)
International functional GI experts finalized Rome IV, the first major update to the Rome criteria since 2006, in December 2014 in Rome, Italy. Rome IV was published in the journal Gastroenterology in May 2016 and officially presented to the gastroenterology professional community at the Digestive Disease Week conference in San Diego, California, USA on May 21-25, 2016.
by Douglas A. Drossman, MD, MACG of the Drossman Center for the Education and Practice of Biopsychosocial Care, the University of North Carolina and the Rome Foundation. Gastroenterology, May 2016.
by Magnus Simren, MD, University of Gothenburg, Gothenburg, Sweden, Olafur S. Palsson, PsyD and William E. Whitehead, PhD, both from the Center for Functional GI and Motility Disorders, University of North Carolina, Chapel Hill, NC, USA. Current Gastroenterology Reports, April 2017
From the IBS Impact blog:
“Behind the Scenes at Rome IV Foundation” Video Humanizes Functional GI Experts, (February 23, 2015)
Other important information on the nature of IBS, symptoms, diagnosis and standards of medical care can be found in the sections below. Pages often also include additional links to good quality, evidence-based information on a variety of IBS/functional GI issues
University of North Carolina/Chapel Hill Center for Functional GI and Motility Disorders
IFFGD International Foundation for Gastrointestinal Disorders
IBS Impact blog post Irritable Bowel Syndrome (IBS) Is Not a Diagnosis of Exclusion
IBS Impact blog post An Evolving Redefinition of Severity in Irritable Bowel Syndrome (IBS)
IBS Impact blog post 15 Common Misconceptions That Shouldn’t Exist About Irritable Bowel Syndrome (IBS)
IBS Impact blog post Irritable Bowel Syndrome (IBS) and the Myth of a Cure
National professional organization guidelines for the diagnosis and/or treatment of IBS
In the United States: American College of Gastroenterology – December 2020 NEW
In the United Kingdom: British Society of Gastroenterology– April 2021
Gastroenterological Society of Australia (GESA) guidance for general practitioners. IBS4GPs.com
Articles or abstracts from leading international researchers on important prevalence, diagnosis, symptom or treatment issues.
Brennan M.R. Spiegel, MD, MSHS
2007 IFFGD Research Award Recipient
then at VA Greater Los Angeles Health System and David Geffen School of Medicine, UCLA, now at Cedars-Sinai Health System and UCLA
The article states that Rome international diagnostic criteria for IBS, based on symptoms, are considered to be 98% accurate. Extensive testing of all people with potential IBS is unnecessary and discouraged, and is usually appropriate only for a few subgroups at higher risk of different GI disorders. Unfortunately studies show that health care providers in local communities are much more likely than IBS/functional GI specialists to still believe erroneously that IBS is a diagnosis of exclusion requiring many tests to rule out other conditions.
Olafur S. Palsson, Psy.D. and William E. Whitehead, Ph.D.
UNC Center for Functional GI & Motility Disorders
, PsyD, University of North Carolina Center for Functional GI and Motility Disorders, USA, , PhD, University of North Carolina Center for Functional GI and Motility Disorders, USA , MD, PhD, University of Gothenburg, Sweden, , MD, MSPH, Ben-Gurion University of the Negev, Israel, and , MD, PhD, University of North Carolina Center for Functional GI and Motility Disorders, USA and University of Gothenburg, Sweden. Gastroenterology, April 2020 (full-text)
The Prevalence and Impact of Overlapping Rome IV-Diagnosed Functional Gastrointestinal Disorders on Somatization, Quality of Life, and Healthcare Utilization: A Cross-Sectional General Population Study in Three Countries
, MBChB, MD, University of Gothenburg, Sweden, , PsyD, University of North Carolina Center for Functional GI and Motility Disorders, USA, , MD, PhD, University of Gothenburg, Sweden, , MD, MSPH, Ben-Gurion University of the Negev, Israel, , PhD, University of North Carolina Center for Functional GI and Motility Disorders, USA and , MD, PhD, University of Gothenburg, Sweden.
American Journal of Gastroenterology, January 2018. Abstract only.
There are many conditions that fall along the spectrum of functional gastrointestinal disorders, also known as disorders of gut-brain interaction. Irritable bowel syndrome (IBS) is the most common condition in this category. This large study conducted in the United States, Canada and the United Kingdom found that approximately a third of adults meet Rome IV criteria for a functional GI disorder, and approximately a third of that subset have two or more functional GI disorders.
Highlights of the Updated Evidence-Based Treatment Monograph
Gastroenterology and Hepatology, November 2018 interview with:
Last update to IBS page: January 2022